Live feed08:30:00·55dPRReleasevia QuantisnowTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic DermatitisByQuantisnow·Wall Street's wire, on your screen.TTRX· Turn Therapeutics Inc.Health Care
